Brief Report: Herpesvirus Viremia, ART Response, and Growth Recovery in Kenyan Children Starting Antiretroviral Therapy in Hospital

High CMV or EBV viremia at admission predicted slower CD4 gain over 6 months in infants starting ART. These data suggest that herpesvirus viremia at baseline may identify a subset of children who will have a slower immunologic response to ART. Further research is needed to determine whether herpesvirus viremia delays ART responses and recovery in children.